Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.52 |
| ▸ | ARG2 | P78540 | 2/20 | 0.52 |
| ▸ | GGT1 | P19440 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600648 | 1.00 | ARG1 (0.52) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL600647 | 1.00 | ARG1 (0.52) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL599813 | 0.94 | ARG1 (0.55) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL599814 | 0.94 | ARG1 (0.55) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL601232 | 0.94 | ARG1 (0.55) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL600736 | 0.92 | ARG1 (0.53) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL602186 | 0.92 | ARG1 (0.53) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL600737 | 0.92 | ARG1 (0.53) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL600192 | 0.88 | GGT1 (0.50) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL602005 | 0.88 | GGT1 (0.50) | ARG1ARG2GGT1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042961-A1 | P53 PEPTIDOMIMETIC MACROCYCLES | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) | 2025-02-06 | — | — | US | claimed |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | MERCK SHARP & DOHME LLC (US) | 2025-01-30 | — | — | US | claimed |
| CN-118829648-A | P53 peptidomimetic macrocycles | 默沙东有限责任公司 | 2024-10-22 | — | — | CN | claimed |
| EP-4444740-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | Merck Sharp & Dohme LLC (US) | 2024-10-16 | — | — | EP | claimed |
| EP-4441067-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | Merck Sharp & Dohme LLC (US) | 2024-10-09 | — | — | EP | claimed |
| WO-2023107353-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023096947-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | MERCK SHARP & DOHME LLC (US) | 2023-06-01 | — | — | WO | claimed |
| EP-2564863-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2017-08-23 | — | — | EP | claimed |
| EP-2564862-B1 | Substituted amino acids for preparing triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2017-08-02 | — | — | EP | claimed |
| CN-101663044-B | Triazole macrocycle systems | AILERON THERAPEUTICS INC | 2014-07-23 | — | — | CN | claimed |
| US-8637686-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2014-01-28 | — | — | US | claimed |
| EP-2564862-A2 | Triazole linked macrocyclic peptides | Aileron Therapeutics, Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2564863-A2 | Triazole linked macrocyclic peptides | Aileron Therapeutics, Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2114428-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | claimed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | claimed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | claimed |
| CN-101663044-A | triazole macrocycle systems | AILERON THERAPEUTICS INC | 2010-03-03 | — | — | CN | claimed |
| EP-2114428-A2 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | claimed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | ARG1 108/4885ARG2 219/4885GGT1 3198/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | ARG1 108/4885ARG2 219/4885GGT1 3198/4885 |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | TP53, MDM4, MDM2 | ARG1 986/4885ARG2 901/4885GGT1 2192/4885 |
| US-20250042961-A1 | P53 PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | ARG1 821/4885ARG2 694/4885GGT1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.